Company profile
Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SERALUTINIB | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04556383 | phase2 | terminated | 2020-10-19 | 2022-06-01 | GB004, Inc. | A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) |
| NCT03926793 | phase1 | completed | 2020-02-04 | 2021-05-05 | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension |
| NCT05934526 | phase3 | completed | 2023-12-28 | 2025-11-27 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) |
| NCT07181382 | phase3 | suspended | 2026-02-01 | 2028-12-01 | GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
| NCT03956862 | phase2 | completed | 2019-05-16 | 2020-07-09 | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | GB001 in Adult Participants With Chronic Rhinosinusitis |
FDA applications (0)
No records yet.